2026 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
China’s biopharma sector is evolving fast, marked by smarter deal-making, bold but challenging pipelines, and groundbreaking approvals. Together, these shifts signal a market pushing beyond its borders to claim global influence.
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
